{"id":"probiotics-vsl-3","safety":{"commonSideEffects":[{"rate":null,"effect":"Bloating"},{"rate":null,"effect":"Flatulence"},{"rate":null,"effect":"Abdominal discomfort"},{"rate":null,"effect":"Mild gastrointestinal symptoms"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"VSL#3 contains eight live bacterial strains (Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii subsp. bulgaricus) that colonize the colon and enhance the intestinal epithelial barrier. These strains produce short-chain fatty acids, compete with pathogenic bacteria, and stimulate local and systemic immune tolerance, reducing inflammation and improving gut dysbiosis-related conditions.","oneSentence":"VSL#3 is a multi-strain probiotic formulation that restores beneficial gut microbiota to improve intestinal barrier function and modulate immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:02:50.253Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Irritable bowel syndrome (IBS)"},{"name":"Ulcerative colitis"},{"name":"Inflammatory bowel disease"},{"name":"Antibiotic-associated diarrhea"},{"name":"Traveler's diarrhea"}]},"trialDetails":[{"nctId":"NCT06508034","phase":"NA","title":"Probiotics for the Prevention of Immunotherapy Induced Colitis in Patients Receiving Immunotherapy","status":"SUSPENDED","sponsor":"Mayo Clinic","startDate":"2024-07-31","conditions":"Malignant Solid Neoplasm","enrollment":12},{"nctId":"NCT05922683","phase":"PHASE2","title":"Maternal Probiotic Intervention to Improve Gut Health","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2023-08-09","conditions":"Environmental Enteric Dysfunction, Stunting","enrollment":76},{"nctId":"NCT05501470","phase":"PHASE2","title":"Probiotic For the Improvement of Environmental Enteropathy in Pregnant Women in Senegal","status":"RECRUITING","sponsor":"Institut Pasteur de Dakar","startDate":"2024-06-06","conditions":"Environmental Enteric Dysfunction","enrollment":76},{"nctId":"NCT05007470","phase":"NA","title":"Alcoholic Liver Disease and the Gut Microbiome","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2022-01-31","conditions":"Alcohol Use Disorder, Alcoholic Liver Disease, Microbiome","enrollment":80},{"nctId":"NCT05767450","phase":"NA","title":"Intervention on New Onset-T1D Children","status":"RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2022-12-16","conditions":"Type 1 Diabetes","enrollment":60},{"nctId":"NCT06609447","phase":"PHASE4","title":"The Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for the Treatment of Moderate Ulcerative Colitis","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-09-21","conditions":"Ulcerative Colitis","enrollment":100},{"nctId":"NCT01765439","phase":"NA","title":"The Effect of VSL#3 Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Charles University, Czech Republic","startDate":"2014-02","conditions":"Crohn Disease, Ulcerative Colitis","enrollment":79},{"nctId":"NCT03423589","phase":"NA","title":"Modulation of Type 1 Diabetes Susceptibility Through the Use of Probiotics","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2018-04-23","conditions":"Type1diabetes, Type1 Diabetes Mellitus","enrollment":30},{"nctId":"NCT03682094","phase":"EARLY_PHASE1","title":"Impact of Probiotics on Oral Microbiota in Older Adults With Dysphagia","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2018-08-27","conditions":"Dysphagia","enrollment":9},{"nctId":"NCT05920018","phase":"NA","title":"Effects of a Combined Supplementation of Conjugated Linoleic Acid (CLA) and Probiotics (Vivomixx®) as add-on to a First-line Immunotherapy in Relapsing-remitting Multiple Sclerosis","status":"RECRUITING","sponsor":"Universität Münster","startDate":"2023-10-02","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":100},{"nctId":"NCT06196450","phase":"PHASE2","title":"Maternal Probiotic Intervention to Improve Gut Health","status":"UNKNOWN","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2023-06-22","conditions":"Environmental Enteric Dysfunction, Gut Microbiota Dysbiosis","enrollment":76},{"nctId":"NCT05967715","phase":"NA","title":"Exercise Training Influences Gut Microbiota and Cardiovascular Health Through Inflammation Control in Adult Hypertensive Population: the MicroFit Study","status":"RECRUITING","sponsor":"University of Bologna","startDate":"2023-04-03","conditions":"Hypertension, Microbiota","enrollment":75},{"nctId":"NCT03907501","phase":"NA","title":"Effects of Triphala and VSL#3 Probiotic Supplementation on Stool Microbiome Profiles and Inflammation","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2019-02-01","conditions":"Human Microbiome","enrollment":75},{"nctId":"NCT00852124","phase":"PHASE1, PHASE2","title":"Safety of VSL#3 in Adult Asthmatics","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2007-02","conditions":"Asthma","enrollment":3},{"nctId":"NCT02276326","phase":"NA","title":"Effects of VSL#3 on Neuro-cognitive Profile of HIV Patients","status":"COMPLETED","sponsor":"Azienda Policlinico Umberto I","startDate":"2014-07","conditions":"HIV Seropositivity, ART","enrollment":20},{"nctId":"NCT05608928","phase":"PHASE2","title":"Ability of the Probiotic Vivomixx to Improve Environmental Enteropathy in Pregnant Women: a Proof of Concept Trial in Bangladesh, Pakistan, Senegal and Zambia","status":"UNKNOWN","sponsor":"Tropical Gastroenterology & Nutrition Group (TROPGAN)","startDate":"2022-12-01","conditions":"Environmental Enteropathy","enrollment":76},{"nctId":"NCT03092427","phase":"NA","title":"Probiotic Treatment in Juvenile Idiopathic Arthritis (JIA)","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-09-04","conditions":"Juvenile Idiopathic Arthritis","enrollment":51},{"nctId":"NCT01635192","phase":"EARLY_PHASE1","title":"Effects of Probiotic VSL#3 on Expression of Small Intestinal Renin-angiotensin System","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2011-12","conditions":"the Local Renin-angiotensin System (RAS) in Small Intestinal Mucosa in Man","enrollment":24},{"nctId":"NCT04256785","phase":"NA","title":"Probiotic VSL#3 for the Treatment of Gastrointestinal Symptoms Associated to Fibromyalgia","status":"COMPLETED","sponsor":"Elena Pita Calandre","startDate":"2018-05-11","conditions":"Fibromyalgia, Gastrointestinal Disease","enrollment":110},{"nctId":"NCT03586622","phase":"NA","title":"One Year Home Monitoring and Treatment of IBS Patients","status":"UNKNOWN","sponsor":"Nordsjaellands Hospital","startDate":"2018-09-23","conditions":"eHealth, Dietary Modification, Probiotics","enrollment":124},{"nctId":"NCT03052179","phase":"NA","title":"The Clinical and Biological Effects Of The Use Of Probiotic VSL#3 In Patients With Oral Lichen Planus","status":"COMPLETED","sponsor":"University College, London","startDate":"2017-08-24","conditions":"Oral Lichen Planus","enrollment":30},{"nctId":"NCT03327051","phase":"PHASE4","title":"Gastric Acid Suppression and Probiotic Colonization","status":"COMPLETED","sponsor":"Stanford University","startDate":"2018-03-20","conditions":"Probiotics","enrollment":39},{"nctId":"NCT03165747","phase":"PHASE2","title":"Effect of VSL#3 on Bone Mineral Density in Postmenopausal Women","status":"TERMINATED","sponsor":"Emory University","startDate":"2017-10-01","conditions":"Menopausal Osteoporosis","enrollment":35},{"nctId":"NCT03415711","phase":"NA","title":"PRObiotic VSL#3® for Maintenance of Clinical and Endoscopic REMission in Ulcerative Colitis","status":"TERMINATED","sponsor":"VSL Pharmaceuticals","startDate":"2017-04-28","conditions":"Ulcerative Colitis","enrollment":14},{"nctId":"NCT03511365","phase":"PHASE1, PHASE2","title":"Effects of Probiotic on Inflammation and Microbiota in Patients With NASH","status":"TERMINATED","sponsor":"Northwell Health","startDate":"2018-05-15","conditions":"Non-Alcoholic Fatty Liver Disease, Probiotics MeSH Descriptor Data 2018, Interleukin-17 MeSH Descriptor Data 2018","enrollment":6},{"nctId":"NCT04006977","phase":"NA","title":"Multistrain Probiotics Reduces UC Depression and Anxiety Scores","status":"UNKNOWN","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2019-10","conditions":"Ulcerative Colitis","enrollment":60},{"nctId":"NCT03704727","phase":"NA","title":"The Effects of Probiotics on Intestinal Permeability in Gastrointestinal Cancer Patients in Chemotherapy","status":"COMPLETED","sponsor":"University of Copenhagen","startDate":"2018-07-01","conditions":"Intestinal Permeability, Gastrointestinal Irritation, Mucositis","enrollment":5},{"nctId":"NCT00179582","phase":"NA","title":"Dose Ranging Study With the Probiotic Combination (VSL#3) in Diarrhea IBS","status":"TERMINATED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2005-01","conditions":"IBS","enrollment":180},{"nctId":"NCT01465802","phase":"PHASE2","title":"Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-12-26","conditions":"Non Small Cell Lung Cancer (NSCLC)","enrollment":236},{"nctId":"NCT02011542","phase":"PHASE2, PHASE3","title":"Probiotic (VSL #3) for Gulf War Illness","status":"TERMINATED","sponsor":"University of Utah","startDate":"2013-09","conditions":"Gulf War Illness","enrollment":29},{"nctId":"NCT03533621","phase":"NA","title":"Gut Microbiome, Adiposity, and Probiotics (GMAP)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2014-09-04","conditions":"Obesity, Childhood","enrollment":45},{"nctId":"NCT03078530","phase":"PHASE2, PHASE3","title":"Probiotic (Visbiome) for Gulf War Illness","status":"UNKNOWN","sponsor":"Ashok Tuteja","startDate":"2013-09-13","conditions":"Gulf War Illness","enrollment":60},{"nctId":"NCT03330678","phase":"NA","title":"Effect of Probiotic Administration on Gut Flora Composition","status":"COMPLETED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2013-12","conditions":"Probiotics","enrollment":14},{"nctId":"NCT01970683","phase":"PHASE3","title":"Probiotics and Recovery From Surgery","status":"TERMINATED","sponsor":"Catholic Health Initiatives","startDate":"2014-08","conditions":"Major Abdominal Operation","enrollment":140},{"nctId":"NCT02448238","phase":"NA","title":"Pilot Study of Oral Probiotic Bacteria Supplementation to Reduce Chronic Immune Activation in HIV-infected Malian Women","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2015-05","conditions":"HIV","enrollment":23},{"nctId":"NCT03115385","phase":"NA","title":"Probiotics and the Gut Microbiome in Obese Hispanic Youth","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2015-05-30","conditions":"Obesity, Abdominal, Adiposity","enrollment":22},{"nctId":"NCT03095963","phase":"NA","title":"Interaction Between Levothyroxine and Probiotics in Hypothyroid Patients","status":"COMPLETED","sponsor":"Azienda USL Modena","startDate":"2014-01-01","conditions":"Hypothyroidism","enrollment":80},{"nctId":"NCT01650025","phase":"NA","title":"Effects of VSL#3 on Metabolic, Endocrine, Lipidomic and Inflammatory Parameters of Pediatric Patients With BMI>90°","status":"COMPLETED","sponsor":"Bambino Gesù Hospital and Research Institute","startDate":"2012-08","conditions":"Obesity","enrollment":48},{"nctId":"NCT00831337","phase":"NA","title":"Evaluation of Probiotics in the Treatment of Portal Hypertension","status":"COMPLETED","sponsor":"Pomeranian Medical University Szczecin","startDate":"2007-04","conditions":"Liver Cirrhosis, Portal Hypertension, Encephalopathy","enrollment":33},{"nctId":"NCT01701297","phase":"PHASE2","title":"VSL#3 and Spontaneous Bacterial Peritonitis","status":"TERMINATED","sponsor":"Nottingham University Hospitals NHS Trust","startDate":"2012-02","conditions":"Decompensated Cirrhosis, Ascites","enrollment":10},{"nctId":"NCT00630838","phase":"PHASE2","title":"Probiotic Prophylaxis of Hirschprung's Disease Associated Enterocolitis (HAEC)","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2006-09","conditions":"Hirschsprung Disease","enrollment":62},{"nctId":"NCT01473290","phase":"PHASE3","title":"Probiotic Therapy in Preventing Gastrointestinal Complications in Patients Undergoing Chemotherapy and Pelvic Radiation Therapy","status":"WITHDRAWN","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"","conditions":"Cognitive/Functional Effects, Constipation, Impaction, and Bowel Obstruction, Diarrhea","enrollment":""},{"nctId":"NCT01686698","phase":"PHASE4","title":"Effect of VSL#3 (Original De Simone Formulation) on Cognitive Function, Risk of Falls and Quality of Life in Patients With Cirrhosis","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2013-03","conditions":"Cirrhosis, Cognitive Dysfunction","enrollment":40},{"nctId":"NCT02545413","phase":"PHASE3","title":"Study to Determine Efficacy of Probiotics in Irritable Bowel Syndrome","status":"WITHDRAWN","sponsor":"Next Gen Pharma India Pvt. Ltd.","startDate":"2016-05","conditions":"Irritable Bowel Syndrome","enrollment":""},{"nctId":"NCT00971711","phase":"PHASE1","title":"Safety Study of Probiotics in Adults With Irritable Bowel Syndrome","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2009-09","conditions":"Irritable Bowel Syndrome","enrollment":21},{"nctId":"NCT00933556","phase":"PHASE2","title":"A Pilot Trial to Determine the Efficacy of VSL#3 for Reducing Colonization by VRE","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2008-10","conditions":"Anti-biotic Resistance","enrollment":90},{"nctId":"NCT01869426","phase":"PHASE4","title":"Impact of Probiotic Preparation VSL#3 on Infants Colics","status":"UNKNOWN","sponsor":"Policlinico Hospital","startDate":"2013-06","conditions":"Infant Colics","enrollment":62},{"nctId":"NCT01831323","phase":"","title":"Evaluation of the Metabolome in Diverticular Disease","status":"UNKNOWN","sponsor":"S.Eugenio Hospital","startDate":"2012-12","conditions":"Simple Diverticular Disease","enrollment":40},{"nctId":"NCT01632462","phase":"PHASE4","title":"A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease","status":"UNKNOWN","sponsor":"Federico II University","startDate":"2012-09","conditions":"Crohn's Disease","enrollment":30},{"nctId":"NCT00944736","phase":"PHASE3","title":"Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's Disease","status":"COMPLETED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2009-07","conditions":"Crohn's Disease","enrollment":12},{"nctId":"NCT01367470","phase":"PHASE4","title":"Influence of Probiotic VSL#3 Administration on Metabolic and Immunological Profile of the Milk of Breastfeeding Mothers","status":"COMPLETED","sponsor":"Policlinico Hospital","startDate":"2010-04","conditions":"Allergy","enrollment":67},{"nctId":"NCT01110447","phase":"PHASE2, PHASE3","title":"Secondary Prophylaxis of Hepatic Encephalopathy With a Probiotic Preparation","status":"COMPLETED","sponsor":"CD Pharma India Pvt. Ltd.","startDate":"2010-04","conditions":"Hepatic Encephalopathy","enrollment":130},{"nctId":"NCT01008293","phase":"PHASE2, PHASE3","title":"Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life","status":"COMPLETED","sponsor":"CD Pharma India Pvt. Ltd.","startDate":"2009-10","conditions":"Chronic Liver Disease, Hepatic Encephalopathy","enrollment":120},{"nctId":"NCT00973908","phase":"PHASE2, PHASE3","title":"Probiotics for the Prevention of Antibiotics Associated Diarrhoea and Clostridium Difficile Associated Diarrhoea","status":"COMPLETED","sponsor":"National Health Service, United Kingdom","startDate":"2010-04","conditions":"Diarrhoea","enrollment":231},{"nctId":"NCT01798329","phase":"PHASE3","title":"ETOS: Minimal Hepatic Encephalopathy in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study","status":"UNKNOWN","sponsor":"A.O. Ospedale Papa Giovanni XXIII","startDate":"2013-03","conditions":"Hepatic Encephalopathy","enrollment":50},{"nctId":"NCT01139736","phase":"PHASE4","title":"Manipulation of Visceral Hypersensitivity With Probiotic Bacteria in Irritable Bowel Syndrome","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2010-07","conditions":"Irritable Bowel Syndrome","enrollment":12},{"nctId":"NCT01638208","phase":"PHASE4","title":"Changes in Gastrointestinal Microbiota Using VSL#3 in Patients With IBS-D","status":"UNKNOWN","sponsor":"Asian Institute of Gastroenterology, India","startDate":"2012-08","conditions":"Irritable Bowel Syndrome","enrollment":40},{"nctId":"NCT01579591","phase":"PHASE3","title":"VSL#3 Versus Placebo in Increasing the Pathological Major Response Rate in Patients With Rectal Cancer","status":"UNKNOWN","sponsor":"Catholic University of the Sacred Heart","startDate":"2012-03","conditions":"Rectal Cancer","enrollment":160},{"nctId":"NCT01548014","phase":"PHASE3","title":"The Effect of a Probiotic Preparation (VSL#3) Plus Infliximab in Children With Crohn's Disease","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2010-01","conditions":"Crohn's Disease","enrollment":1},{"nctId":"NCT01032941","phase":"PHASE1, PHASE2","title":"The Effect of Probiotics (VSL) on Portal Hypertension","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2009-12","conditions":"Portal Hypertension","enrollment":18},{"nctId":"NCT01179789","phase":"EARLY_PHASE1","title":"New E-Service for a Dietary Approach to the Elderly","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2009-10","conditions":"Aged, Healthy","enrollment":48},{"nctId":"NCT01241201","phase":"NA","title":"Intestinal Barrier Function and Probiotics.","status":"COMPLETED","sponsor":"TNO","startDate":"2010-10","conditions":"Intestinal Permeability, Challenge Test, Intestinal Health","enrollment":32},{"nctId":"NCT01069445","phase":"NA","title":"Potential Benefits of Dietary Advices Alone or Associated to Nutraceutical Food Supplements Argan Oil, VSL#3 Probiotic Blend, 5203-L Fruit Extract Terpene","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2010-03","conditions":"Healthy Elderly People","enrollment":48},{"nctId":"NCT00786123","phase":"NA","title":"Exploring the Mechanism of a Probiotic Combination VSL#3 in Irritable Bowel Syndrome","status":"COMPLETED","sponsor":"National University Hospital, Singapore","startDate":"2006-05","conditions":"Irritable Bowel Syndrome","enrollment":40},{"nctId":"NCT01178372","phase":"PHASE4","title":"Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis","status":"UNKNOWN","sponsor":"Govind Ballabh Pant Hospital","startDate":"2008-09","conditions":"Hepatic Encephalopathy","enrollment":""},{"nctId":"NCT01134692","phase":"PHASE3","title":"Probiotics for Portal Hypertension","status":"UNKNOWN","sponsor":"Govind Ballabh Pant Hospital","startDate":"","conditions":"Cirrhosis, Varices, Esophageal","enrollment":""},{"nctId":"NCT00099723","phase":"PHASE1","title":"The Effect of a Probiotic on Hepatic Steatosis","status":"TERMINATED","sponsor":"VSL Pharmaceuticals","startDate":"2004-10","conditions":"Fatty Liver","enrollment":30},{"nctId":"NCT00114465","phase":"PHASE4","title":"VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease","status":"COMPLETED","sponsor":"Orphan Australia","startDate":"2005-06","conditions":"Crohn's Disease","enrollment":38},{"nctId":"NCT00951548","phase":"NA","title":"Food Supplementation With VSL#3 as a Support to Standard Pharmaceutical Therapy in Ulcerative Colitis","status":"COMPLETED","sponsor":"VSL Pharmaceuticals","startDate":"2006-10","conditions":"Ulcerative Colitis","enrollment":144},{"nctId":"NCT00794924","phase":"NA","title":"Probiotics and Hospital Outcome in the Elderly","status":"COMPLETED","sponsor":"Kaplan-Harzfeld Medical Center","startDate":"2004-02","conditions":"Diarrhea, Constipation","enrollment":345},{"nctId":"NCT00722410","phase":"PHASE1, PHASE2","title":"Probiotics for Eradication of Carbapenem Resistant Klebsiella Pneumonia","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2008-09","conditions":"Anti-Biotic Resistance, Klebsiella Pneumoniae","enrollment":60},{"nctId":"NCT00678613","phase":"PHASE2, PHASE3","title":"Role of Probiotics in the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients: A Randomized Placebo Control Trial","status":"UNKNOWN","sponsor":"All India Institute of Medical Sciences","startDate":"2007-07","conditions":"Spontaneous Bacterial Peritonitis, Liver Cirrhosis","enrollment":250},{"nctId":"NCT00175292","phase":"PHASE3","title":"A Randomized Controlled Trial of VSL#3 for the Prevention of Endoscopic Recurrence Following Surgery for Crohn's Disease.","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2003-12","conditions":"Crohn's Disease, Inflammatory Bowel Disease","enrollment":120},{"nctId":"NCT00319007","phase":"PHASE2","title":"Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2006-04","conditions":"Adenomatous Polyposis Coli","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Probiotics(VSL#3)","genericName":"Probiotics(VSL#3)","companyName":"Govind Ballabh Pant Hospital","companyId":"govind-ballabh-pant-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VSL#3 is a probiotic preparation that has been studied in clinical trials for various conditions, including allergy, asthma, portal hypertension, spontaneous bacterial peritonitis, and liver cirrhosis. The mechanism of action of VSL#3 is related to its enzymatic activity, specifically as a sulfatase enzyme.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}